We next performed doxorubicin retention assay upon ABCC1 inhibition to check the retention of doxorubicin in various breast cancer cell lines (MDA-MB-231, BT-474, MCF-7 and HCC-1806) as well as in primary breast cancer tissue samples. This evidence concerns the gene ABCC1 and breast carcinoma.